Core Insights - The article highlights the potential of FXI-targeted drugs to provide safer anticoagulation options without significantly increasing bleeding risks, with multiple drugs expected to enter critical data readout phases starting in 2026 [1][2] Market Overview - The global market for anticoagulant drugs reached $52.9 billion in 2023 and is projected to exceed $110 billion by 2033, driven by the aging population and rising cardiovascular disease prevalence [1] - The demand for anticoagulant drugs is steadily increasing, particularly in China, which lays a solid foundation for the development and commercialization of new anticoagulant drugs [1] Drug Development Trends - Traditional anticoagulants face challenges in balancing efficacy and bleeding risks, leading to the emergence of new oral anticoagulants (NOACs) that have improved upon the limitations of warfarin [1] - Major NOACs like Bayer's Xarelto (rivaroxaban) and BMS/Pfizer's Eliquis (apixaban) have achieved sales exceeding $1 billion, but still cannot avoid bleeding complications [1] - The expiration of core patents for these drugs will allow generics to enter the market, prompting a necessary shift towards the development and iteration of next-generation anticoagulants [1] FXI as a Target - FXI is identified as a key factor in pathological thrombosis, with studies showing that individuals with hereditary FXI deficiency have a significantly lower incidence of thrombotic events without a notable increase in spontaneous bleeding risk [2] - FXI inhibitors are being developed through various technological routes, including small molecules, monoclonal antibodies, and siRNA, targeting multiple indications such as atrial fibrillation, stroke prevention, and venous thromboembolism [2] Clinical Trials and Progress - Bayer's Asundexian has shown mixed results in pivotal Phase III trials, while BMS/Johnson & Johnson's Milvexian has faced challenges in its clinical trials [2] - Novartis's Abelacimab has received FDA fast track designation for two indications and is advancing in Phase III trials, while Regeneron's dual pipeline of FXI monoclonal antibodies is also in Phase III [2] - siRNA drugs are being explored for longer-lasting and safer treatment options, with companies like Ribopharma and Jingyin Pharmaceuticals making progress in Phase II studies [2]

Group 1 - The demand for antithrombotic drugs is expanding due to the aging population and rising prevalence of cardiovascular diseases, with the global market size reaching $52.9 billion in 2023 and expected to exceed $110 billion by 2033 [2] - Anticoagulants are the core category within this market, showing steady growth, particularly in China, which provides a broad market foundation for the development and commercialization of new anticoagulants [2] - The upgrade window for anticoagulants has arrived, with the next generation of drugs poised for development as traditional anticoagulants struggle to balance efficacy and bleeding risks [2] Group 2 - FXI is identified as a key target for the next generation of anticoagulants due to its unique advantages of "precise anticoagulation and low bleeding risk," with multiple FXI/FXIa inhibitors currently in registration clinical stages globally [3] - Bayer's Asundexian and BMS/Johnson & Johnson's Milvexian are among the small molecule FXIa inhibitors undergoing clinical trials, with varying degrees of success in different indications [4] - In the realm of monoclonal antibodies, Novartis' Abelacimab has received FDA fast track designation for stroke prevention in atrial fibrillation and cancer-related thrombosis, while Regeneron is advancing two FXI monoclonal antibodies into Phase III trials [4] Group 3 - Recommended companies include Heng Rui Medicine (01276), with related companies being Reblozyl Bio-B (06938) and Jingyin Pharmaceutical [5]

Investment Rating - The report assigns an "Overweight" rating for the industry [1] Core Insights - The demand for antithrombotic drugs is expanding, driven by the increasing prevalence of thrombotic diseases, particularly due to aging populations and rising cardiovascular disease rates. The global market for antithrombotic drugs reached $52.9 billion in 2023 and is expected to exceed $110 billion by 2033, with a compound annual growth rate (CAGR) of 7.7% from 2023 to 2033 [10][19] - The next generation of anticoagulants is on the horizon, with a focus on drugs targeting Factor XI (FXI) to provide effective anticoagulation with lower bleeding risks. Multiple FXI inhibitors are currently in clinical development, indicating a significant shift in the anticoagulation landscape [3][25] - The report highlights the competitive landscape for FXI inhibitors, which include small molecules, monoclonal antibodies, and siRNA therapies, all aiming to balance efficacy and safety in anticoagulation treatment [30][36] Summary by Sections 1. Expansion of Antithrombotic Drug Market - Thrombotic diseases are a leading cause of death globally, with an estimated 26.7 million cases in 2024, projected to rise to 29.1 million by 2034. Risk factors include aging, obesity, and metabolic disorders [9][10] - The global antithrombotic drug market is projected to grow from $52.9 billion in 2023 to $110.6 billion by 2033, with a CAGR of 7.7% [10][19] 2. Upgrade Window for Anticoagulants - The anticoagulant market is expected to grow from $28 billion in 2020 to $33 billion in 2024, with a CAGR of 4.2%. The Chinese market is also rapidly developing, projected to reach $9 billion by 2024 [15][19] 3. FXI Opens a New Era in Anticoagulation - FXI inhibitors are seen as ideal targets for new anticoagulants due to their ability to reduce thrombotic events without significantly increasing bleeding risks. Current research shows that individuals with low FXI activity have a significantly reduced risk of thrombotic events [25][27] - Multiple FXI inhibitors are in advanced clinical stages, including small molecules like Asundexian and monoclonal antibodies like Abelacimab, indicating a robust pipeline for future anticoagulant therapies [30][32]

Core Viewpoint - Sirius Therapeutics has submitted its listing application to the Hong Kong Stock Exchange, with a valuation of approximately $253 million after its Series B funding round in April 2025, backed by prominent investors [1][2]. Group 1: Company Overview - Sirius Therapeutics was established in 2021 and focuses on developing siRNA therapies [1]. - The company is co-founded by top healthcare investment firms OrbiMed Entities and Creacion Ventures, holding over 40% of shares, with Tencent's investment arm holding 8.14% and Hancan Capital holding over 13% [1]. - The company reported a net loss of 309 million yuan and 342 million yuan for 2023 and 2024, respectively, totaling 651 million yuan in losses [3]. Group 2: Financial Performance - In the first half of 2025, Sirius Therapeutics achieved a net profit of 34.46 million yuan, marking its first profitable period, primarily driven by non-recurring income [3][4]. - The company generated 144 million yuan in other income, a significant increase from 4.51 million yuan in the same period last year, largely due to a strategic partnership with CRISPR Therapeutics [3][4]. Group 3: Product Pipeline and Challenges - The core product, SRSD107, is in Phase II clinical trials for venous thromboembolism, while two key products, SRSD216 and SRSD384, are also in various stages of development [5][6]. - The company faces significant competition in the FXI/FXIa inhibitor space, with several competitors already in Phase III trials, including drugs from Novartis, Bayer, and Johnson & Johnson [7][8]. - Sirius Therapeutics has 65 patents and applications, but only one has been granted, with 32 critical patents pending, posing potential risks in a competitive biopharmaceutical landscape [9].

Core Insights - Novartis will present data from 19 abstracts related to its cardiovascular portfolio at the 2025 European Society of Cardiology Congress in Madrid from August 29 to September 1, 2025 [2][3] - The company aims to showcase innovative treatments that can significantly improve cardiovascular outcomes, focusing on established treatments like Entresto and Leqvio, as well as pipeline assets such as pelacarsen and abelacimab [3][7] Presentation Highlights - Pelacarsen will be featured in multiple presentations, including its effect on reducing the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease [4][5] - Leqvio's impact on patient quality of life will be highlighted in two VictORION studies, along with its efficacy as a cholesterol-lowering monotherapy [5][6] - The PARACHUTE-HF study will evaluate the efficacy and safety of Entresto in treating heart failure with reduced ejection fraction due to chronic Chagas disease [5][6] Research Focus - Novartis is dedicated to addressing significant unmet needs in cardiovascular disease through advanced science and technology, particularly in genetically driven risk factors and common heart conditions [7][10] - The company collaborates with patients, healthcare professionals, and organizations globally to enhance cardiovascular care beyond medication [8][10]